We are delighted to announce the appointment of Hannah Crawford as Interim Chair of the Bionics Institute Board.
Hannah has been an integral part of our governance team for several years as a Non-Executive Director and Chair of the Finance & Risk Committee. Her leadership, financial acumen and strategic expertise have been instrumental in supporting the Institute’s growth and ensuring robust oversight across all areas of operation.
She brings to this new role a wealth of experience in corporate finance, mergers and acquisitions, and organisational governance. Hannah began her career in chartered accounting with Arthur Andersen and Ernst & Young, and later spent over a decade at Grant Samuel, advising both listed and unlisted companies on strategic financial decisions.
In addition to her work with the Bionics Institute, Hannah currently serves as Chair of Local Guardians, Non-Executive Director of Confoil Australia & New Zealand, and a member of the Finance and Audit Committee of Melbourne Grammar School. She has also held directorships with Alfred Health, Australian Red Cross Lifeblood, and Neurosciences Victoria.
Her appointment as Interim Chair comes at an exciting time for the Bionics Institute, as we continue to expand the impact of our research and innovation in hearing, vision, neurological and chronic health conditions.
I am incredibly privileged to step into the role of Interim Chair of the Bionics Institute. Since becoming involved with the Institute in 2022, I have been continually astounded by the extraordinary work of our research team. It is an honour to help lead an Institute dedicated to transforming the lives of people living with challenging health conditions, and I am excited to contribute to shaping its future.
Hannah’s deep knowledge of our organisation and her passion for health and medical research make her ideally positioned to guide the Institute through this transition period. The Board is confident that her leadership will help steer the Institute through our next phase of development and discovery.
We thank Hannah for stepping into this vital leadership role and look forward to working closely with her as we continue delivering on our mission to improve lives through medical bionics.
